Clarissa Desjardins, Ph.D.
CEO and Founder
Dr. Clarissa Desjardins founded Clementia in 2011 and has served as the company’s chief executive officer since then. Prior to Clementia, she was CEO at the Centre d’excellence en médecine personnalisée (CEPMED), a Montreal-based federally and privately funded non-profit enterprise created to promote personalized medicine.
Dr. Desjardins is an award-winning entrepreneur with more than 18 years of biotechnology experience. She has founded three successful biotech companies, leading all aspects of company creation including conception and financing. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. Dr. Desjardins also co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was executive vice-president of Corporate Development.
She received the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of the top young Canadians likely to influence the future by the Globe and Mail. Dr. Desjardins has been a board member of numerous companies including the scientific advisory council of the Canadian Academy of Sciences.
Dr. Desjardins earned a doctorate in Neurology and Neurosurgery from McGill University’s Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre.
Donna Grogan, M.D.
Chief Medical Officer
Dr. Grogan joined Clementia with nearly 20 years of experience in the pharmaceutical industry, and is a board certified internal medicine physician with 15 years of experience in clinical medicine.
During her time in the industry, she has led numerous investigational new drug applications, design and execution of clinical programs and new drug applications across multiple therapeutic areas including respiratory, cardiovascular, and orphan diseases. Dr. Grogan has been involved with multiple high-profile product approvals including Lunesta®, Xopenex HFA®, Brovana™ and most recently the EMA authorization of Vyndaqel® (tafamidis) for the treatment of the rare neurologic disease Transthyretin Familial Amyloid Polyneuropathy. She was a key presenter at the FDA’s Division of Neurology Advisory Committee Meeting on tafamidis.
Dr. Grogan has extensive experience with international regulatory authorities, including the U.S. Food and Drug Administration (FDA), The European Medicines Agency (EMA) and the Pharmaceuticals and Medical Devices Agency (PMDA), Japan.
Dr. Grogan received her Bachelor of Arts degree from College of the Holy Cross, Mass. She earned a doctorate from University of Illinois College of Medicine, Ill.
Chief Development Officer
Mr. Packman joined Clementia with more than two decades of international experience in regulatory affairs, manufacturing and clinical operations leadership, and orphan drug development.
Mr. Packman has led drug development efforts at several biotechnology companies. Most recently, he served as chief development officer for Apofore Corporation, a start-up focused on the development of novel diabetes therapeutics. Prior to Apofore, Mr. Packman was Vice President of drug development operations at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. He was development team leader for Vyndaqel® (tafamidis), now approved in Europe for the treatment of the orphan disease transthyretin familial amyloid polyneuropathy. Mr. Packman has also headed development operations at Oscient Pharmaceuticals and worldwide business operations for the regulatory affairs division of PAREXEL International Corporation.
Mr. Packman earned a Bachelor of Arts degree in biology from Colby College and an MBA with highest honors from the F. W. Olin Graduate School of Business Administration at Babson College, Mass.
Chief Commercial Officer
Mr. Grinstead joined Clementia with 30 years of commercial experience in the biopharmaceutical industry, during which time he has played a key role in helping patients secure access to medications.
Mr. Grinstead supported several biopharmaceutical companies in the development and implementation of their value-based pricing and reimbursement strategies while a consultant at Medical Marketing Economics. He was senior vice president of commercial operations at Synageva BioPharma where he established a global commercial footprint and helped raise money for the clinical stage biotech. Mr. Grinstead served as vice president of government affairs at Alexion with responsibilities in the commercial, policy, and pricing-reimbursement functions, including the design and implementation of Alexion’s OneSource™ patient education and access support service. He led the patient and product services group for the lysosomal storage diseases franchise at Genzyme and the pricing and reimbursement functions for Amgen’s rheumatology and anemia brands. Mr. Grinstead also served as president of the Safety Net Foundation and the Complement Foundation, two non-profit organizations that provide drugs at no cost to qualified individuals.
Mr. Grinstead received a Bachelor of Arts degree from Westmont College, Calif.
Chief Financial Officer
Mr. Singer joined Clementia with more than 15 years of financial management experience in the pharmaceutical industry. His past experience includes senior finance and governance roles at organizations including Bedrocan Corp, Thallion Pharmaceuticals and its predecessor companies Caprion Pharmaceuticals and Ecopia BioSciences. Mr. Singer managed the launch of Caprion's Initial Public Offering (IPO), as well as the merger of Caprion with Ecopia. Mr. Singer currently serves on the board of Aurora Inc., and previously served as Chairman of the board of Warnex, Inc. and continued on the board when the company merged with Diagnos, Inc.
A chartered professional accountant, Mr. Singer holds a Bachelor of Commerce degree from Concordia University and a Master's degree from McGill University.